DOI: org/10.1016/j.bbrc.2003.09.086 34
Lancet Diabetes Endocrinol 2024;12:51-60.PubMed 54

The methodology included: Identification of 50+ key manufacturers across North America, Europe, Asia-Pacific, and Latin America Product mapping across short-acting GLP-1 agonists, long-acting GLP-1 agonists, dual-action therapies (GLP-1/GIP), and emerging tri-agonist candidates Analysis of reported and modeled annual revenues specific to GLP-1 drug portfolios Coverage of manufacturers representing 75-80% of global market share in 2024 Extrapolation using bottom-up (prescription volume ASP by country/region) and top-down (manufacturer revenue validation) approaches to derive segment-specific valuations across drug type (short-acting, long-acting, dual-action), distribution channel (hospital pharmacies, retail pharmacies, online pharmacies), indication (type 2 diabetes, obesity, cardiovascular diseases), and administration route (subcutaneous injection, oral, inhalation) Download Free Sample Kindly complete the form below to receive a free sample of this Report This is really good guys

For context, Lillys tirzepatide has outperformed Novos semaglutide for weight loss in adults with obesity , a key factor in doctors prescribing decisions
For people exploring the most affordable tirzepatide or affordable semaglutide options, compounding pharmacies have become a popular route
There is also the access barrier of the medical system itself